EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy

Thanida Chanpong, Watee Seesuay, Wararat Chiangjong, Piamsiri Jiramornimit, Sarinthip Preedagasamzin, Korakot Atjanasuppat, Bunyada Jittorntrum, Somsak Prasongtanakij, Supannikar Tawinwung, Sulada Pukiat, Chonticha Saisawang iD, Suparerk Borwornpinyo und 4 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0284708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Thanida Chanpong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Bacteriophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Science and Technology Development Agency, Thailand, Thailand Science Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hodgkin’s lymphoma and anaplastic large cell lymphoma, especially relapsed or refractory diseases, could recently be cured by CD30-targeted immunotherapy. However, the CD30 antigen releases the soluble ectodomain of CD30, which might obscure the targeted therapy. Therefore, the membrane epitope of CD30 (mCD30), left on the cancer cells, might be a prospective target for lymphoma treatment. The discovery of novel mCD30 monoclonal antibodies (mAbs) using phage technology yielded 59 potential human single-chain variable fragments (HuscFvs). Ten candidate HuscFv clones have been selected based on various methods, i.e., direct PCR, ELISA and western blot assays, and nucleotide sequencing techniques. Fortunately, only one potential HuscFv clone, clone #A4, was determined by the prediction of HuscFv-peptide molecular docking and the binding affinity test using isothermal titration calorimetry. Finally, we proved that the HuscFv #A4, which had a binding affinity ( K d ) of 421e-9 ± 2.76e -6 M, might be the novel mCD30 mAb. We generated chimeric antigen receptor-modified T lymphocytes using HuscFv #A4 as an antigen detection part (anti-mCD30-H4CART). The cytotoxicity assay of anti-mCD30-H4CART cells showed significant eradication of the CD30-expressing cell line, K562 (p = 0.0378). We found a novel mCD30 HuscFv using human phage technology. We systematically examined and proved that our HuscFv #A4 could specifically eradicate CD30-expressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Chain AntibodiesBacteriophagesHumansMolecular Docking SimulationAntibodies, MonoclonalPeptide LibraryKi-1 AntigenImmunotherapy

Substanzen

Single-Chain AntibodiesAntibodies, MonoclonalPeptide LibraryKi-1 Antigen

Autor:innen und Institutionen

  • Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand.
  • Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Office of Research, Academic Affairs and Innovation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Chonticha Saisawang, Khanit Sa-Ngiamsuntorn, Usanarat Anurathapan

Förderung

  • the National Science and Technology Development Agency, Thailand
  • Thailand Science Research and Innovation

Zitieren

APA

Chanpong, T., Seesuay, W., Chiangjong, W., Jiramornimit, P., Preedagasamzin, S., Atjanasuppat, K., Jittorntrum, B., Prasongtanakij, S., Tawinwung, S., Pukiat, S., Saisawang, C., Borwornpinyo, S., Sa-Ngiamsuntorn, K., Chaichumpa, W., Hongeng, S., & Anurathapan, U. (2023). A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0284708

Vancouver

Chanpong T, Seesuay W, Chiangjong W, Jiramornimit P, Preedagasamzin S, Atjanasuppat K, et al. A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy. PLOS ONE. 2023. doi:10.1371/journal.pone.0284708

BibTeX
@article{Chanpong2023,
  author = {Chanpong, Thanida and Seesuay, Watee and Chiangjong, Wararat and Jiramornimit, Piamsiri and Preedagasamzin, Sarinthip and Atjanasuppat, Korakot and Jittorntrum, Bunyada and Prasongtanakij, Somsak and Tawinwung, Supannikar and Pukiat, Sulada and Saisawang, Chonticha and Borwornpinyo, Suparerk and Sa-Ngiamsuntorn, Khanit and Chaichumpa, Wanpen and Hongeng, Suradej and Anurathapan, Usanarat},
  title = {A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0284708}
}
Kostenlos starten →